Original title: Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting StentA Randomized, Controlled, Noninferiority Trial.NEXT trial. Reference: Masahiro Natsuaki et al. J Am CollCardiol 2013;62:181–90. Drug-eluting stents with biodegradable polymer were designed to counteract the long-term adverse effects on the vascular wall of permanent polymer. This prospective, multicenter, randomized, non-inferiority design study, compared the biolimus eluting stent with…
Cilostazol reduces restenosis of DES in lesions larger than 40 mm.
Original title: Comparison of Dual Versus Triple Antiplatelet Therapy After Drug-Eluting Stent According to Stent Length (from the Pooled Analysis of DECLARE Trials). Reference: Seung-Whan Lee et al. Am J Cardiol 2013, article in press. Cilostazol, an inhibitor of phosphodiesterase III , associated with aspirin and clopidogrel showed decrease angiographic restenosis both in conventional stents as well as…
Paclitaxel eluting balloon . More effective in restenosis of BMS than DES
Original title: A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. Referencia: Seiji Habara et al. Am Heart J 2013;166:527-533.e2. Paclitaxel – eluting balloons have recently emerged as an option for treating in-stent restenosis, both conventional stents ( BMS ) and with drugs (DES ).…
Everolimus Eluting Stent in multiple vessels with short SYNTAX score
Original title: A Clinical and Angiographic Study of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With Multivessel Coronary Artery Disease. The EXECUTIVE (EXecutive RCT: Evaluating XIENCE V in a Multi Vessel Disease) Trial. Reference: Flavio Ribichini et al. J Am Coll Cardiol Intv 2013. Article in press. Drug-eluting stents (DES ) have emerged…
2nd generation drug-eluting stents intended for left main coronary artery
Original title: Zotarolimus- versus Everolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease. ISAR-LEFT MAIN 2 Study. Reference: Julinda Mehilli et al. J Am Coll Cardiol, article in press. Improvements in 2nd generation drug-eluting stents led to increased efficiency and safety , however there is little information on these new platforms to treat left main coronary artery .…
Zotarolimus-eluting stent in-stent restenosis
Original title: Clinical Outcomes of the Resolute Zotarolimus-Eluting Stent in Patients With In-Stent Restenosis Two-Year Results From a Pooled Analysis. Reference: Gert Richardt et al. J Am Coll Cardiol Intv 2013, article in press. Previous studies reported a target lesion revascularization (TLR) of 15% and target vessel (TVR) of 22% after a year of treating an injury-stent restenosis.…
Pharmacological stent intimal coverage with overlap versus no overlap
Original title: Tissue coverage and neointimal hyperplasia in overlap versus nonoverlap segments of drug-eluting stents 9 to 13 months after implantation: In vivo assessment with optical coherence tomography. Reference: Juan Luis Gutiérrez-Chico et al. Am Heart J 2013;166:83-94.e3. The drug-eluting stent’s (DES) overlapping effect over neointimal healing is not completely understood. Drug overdose, large amounts of polymer and…
DES versus Bare in primary angioplasty at five years. Initial advantage is reducing
Original: title Long-Term Outcome After Drug-Eluting VersusBare-Metal Stent Implantation in Patients WithST-Segment Elevation Myocardial Infarction. 5 Years Follow-Up From the Randomized DEDICATION (Drug Elution and DistalProtection in Acute Myocardial Infarction) Trial. Reference: Lene Holmvang et al. J Am CollCardiolIntv 2013, article in press. Primary angioplasty reduced mortality and reinfarction compared with thrombolytics in patients experiencing an ST…
Double DES in bifurcations, double thrombosis risk
Original title: Late Thrombosis After Double Versus Single Drug-Eluting Stent in the Treatment of Coronary Bifurcations A Meta-analysis of Randomized and Observational Studies. Reference: Marco Zimarino et al. J Am Coll Cardiol Intv 2013. Article in press. In the era of drug-eluting stents, (DES), several randomized and observational studies have been conducted trying to find the best strategy…
First results of bioabsorbable metal scaffolds DREAMS
Original title: Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Reference: Michael Haude et al. Lancet 2013; 381: 836–44. Bioabsorbable scaffolds could improve vasomotion, remodelling and facilitate new interventions, both percutaneous and surgical. This new bioabsorbable scaffold, different from the…